Upper Tract Urothelial Carcinoma: A Narrative Review of Current Surveillance Strategies for Non-Metastatic Disease

被引:3
|
作者
Klemm, Jakob [1 ,2 ]
Bekku, Kensuke [2 ,3 ]
Abufaraj, Mohammad [2 ,4 ]
Laukhtina, Ekaterina [2 ,5 ]
Matsukawa, Akihiro [2 ,6 ]
Parizi, Mehdi Kardoust [2 ]
Karakiewicz, Pierre I. [7 ]
Shariat, Shahrokh F. [2 ,5 ,8 ,9 ,10 ,11 ,12 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Dept Urol, D-20251 Hamburg, Germany
[2] Med Univ Vienna, Comprehens Canc Ctr, Dept Urol, A-1090 Vienna, Austria
[3] Okayama Univ, Dept Urol Dent & Pharmaceut Sci, Grad Sch Med, Okayama 7008525, Japan
[4] Jordan Univ Hosp, Univ Jordan, Dept Special Surg, Div Urol, Amman 11733, Jordan
[5] Sechenov Univ, Inst Urol & Reprod Hlth, Moscow 119991, Russia
[6] Jikei Univ Sch Med, Dept Urol, Tokyo 1058461, Japan
[7] Univ Montreal, Canc Prognost & Hlth Outcomes Unit, Hlth Ctr, Montreal, PQ H2X 3E4, Canada
[8] Al Ahliyya Amman Univ, Hourani Ctr Appl Sci Res, Amman 11942, Jordan
[9] Karl Landsteiner Inst Urol & Androl, A-1090 Vienna, Austria
[10] Weill Cornell Med Coll, Dept Urol, New York, NY 10065 USA
[11] Univ Texas Southwestern, Dept Urol, Dallas, TX 75390 USA
[12] Charles Univ Prague, Fac Med 2, Dept Urol, Prague 25250, Czech Republic
关键词
upper tract urothelial carcinoma; urothelial carcinoma; surveillance; follow-up; UPPER URINARY-TRACT; KIDNEY-SPARING SURGERY; RADICAL NEPHROURETERECTOMY; SEGMENTAL URETERECTOMY; ONCOLOGIC OUTCOMES; INTRAVESICAL RECURRENCE; CONDITIONAL SURVIVAL; RISK STRATIFICATION; RENAL-FUNCTION; ASSOCIATION;
D O I
10.3390/cancers16010044
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Upper tract urinary carcinoma (UTUC) is a rare type of cancer affecting the urinary system. Patients with UTUC often undergo surgeries like kidney-sparing surgery or radical nephroureterectomy. However, even after treatment, there remains a risk of the cancer recurring in different parts of the body. This narrative review aims to better understand the frequency and locations of such recurrences, which is crucial for effectively monitoring patients after their initial treatment. Currently, there is limited information on the optimal methods for tracking patients post-surgery, and on how early detection of cancer, before the appearance of symptoms, might improve health outcomes. This article presents the most important current guideline recommendations and elucidates the evidence behind them. Exploring new imaging technologies and improving methods for assessing patient risk, can potentially lead to more personalized and effective monitoring plans in the near future.Abstract Non-metastatic upper urinary tract carcinoma (UTUC) is a comparatively rare condition, typically managed with either kidney-sparing surgery (KSS) or radical nephroureterectomy (RNU). Irrespective of the chosen therapeutic modality, patients with UTUC remain at risk of recurrence in the bladder; in patients treated with KSS, the risk of recurrence is high in the remnant ipsilateral upper tract system but there is a low but existent risk in the contralateral system as well as in the chest and in the abdomen/pelvis. For patients treated with RNU for high-risk UTUC, the risk of recurrence in the chest, abdomen, and pelvis, as well as the contralateral UT, depends on the tumor stage, grade, and nodal status. Hence, implementing a risk-stratified, location-specific follow-up is indicated to ensure timely detection of cancer recurrence. However, there are no data on the type and frequency/schedule of follow-up or on the impact of the recurrence type and site on outcomes; indeed, it is not well known whether imaging-detected asymptomatic recurrences confer a better outcome than recurrences detected due to symptoms/signs. Novel imaging techniques and more precise risk stratification methods based on time-dependent probabilistic events hold significant promise for making a cost-efficient individualized, patient-centered, outcomes-oriented follow-up strategy possible. We show and discuss the follow-up protocols of the major urologic societies.
引用
收藏
页数:14
相关论文
共 50 条
  • [31] Update on systemic treatment of upper tract urothelial carcinoma: a narrative review of the literature
    Gust, Kilian M.
    Resch, Irene
    D'Andrea, David
    Shariat, Shahrokh F.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2021, 10 (10) : 4051 - 4061
  • [32] Adjuvant Radiotherapy for Upper Tract Urothelial Carcinoma: Systematic Review and Meta-Analysis
    Zalay, Osbert
    Yan, Michael
    Sigurdson, Samantha
    Malone, Shawn
    Vera-Badillo, Francisco Emilio
    Mahmud, Aamer
    CURRENT ONCOLOGY, 2023, 30 (01) : 19 - 36
  • [33] Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinoma
    Locke, Jennifer A.
    Hamidizadeh, Reza
    Kassouf, Wassim
    Rendon, Ricardo A.
    Bell, David
    Izawa, Jonathan
    Chin, Joseph
    Kapoor, Anil
    Shayegen, Bobby
    Lattouf, Jean-Baptiste
    Saad, Fred
    Lacombe, Louis
    Fradet, Yves
    Fairey, Adrien S.
    Jacobson, Niels-Eric
    Drachenberg, Darrel E.
    Cagiannos, Ilias
    So, Alan I.
    Black, Peter C.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2018, 12 (08): : 243 - 251
  • [34] Current Knowledge on Genomic Profiling of Upper Tract Urothelial Carcinoma
    De Lorenzis, Elisa
    Albo, Giancarlo
    Longo, Fabrizio
    Bebi, Carolina
    Boeri, Luca
    Montanari, Emanuele
    GENES, 2021, 12 (03) : 1 - 19
  • [35] Bladder Recurrence Following Upper Tract Surgery for Urothelial Carcinoma: A Contemporary Review of Risk Factors and Management Strategies
    Mertens, Laura S.
    Sharma, Vidit
    Matin, Surena F.
    Boorjian, Stephen A.
    Thompson, R. Houston
    Van Rhijn, Bas W. G.
    Masson-Lecomte, Alexandra
    EUROPEAN UROLOGY OPEN SCIENCE, 2023, 49 : 60 - 66
  • [36] Swedish National Guidelines on Urothelial Carcinoma: 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma
    Liedberg, Fredrik
    Kjellstrom, Sofia
    Lind, Anna-Karin
    Sherif, Amir
    Soderkvist, Karin
    Falkman, Karin
    Thulin, Helena
    Aljabery, Firas
    Papantonio, Dimitrious
    Strock, Viveka
    Ofverholm, Elisabeth
    Jerlstrom, Tomas
    Sandzen, Johan
    Verbiene, Ingrida
    Ullen, Anders
    SCANDINAVIAN JOURNAL OF UROLOGY, 2022, 56 (02) : 137 - 146
  • [37] Narrative review of nephron-sparing surgical management of upper tract urothelial carcinoma: is there a role for distal ureterectomy, segmental ureterectomy, and partial nephrectomy
    Saini, Sumit
    Deveshwar, Shaun Paul
    Hemal, Ashok Kumar
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2024, 13 (01) : 156 - 164
  • [38] Do metastatic upper tract urothelial carcinoma and bladder carcinoma have similar clinical responses to systemic chemotherapy? A Japanese multi-institutional experience
    Kikuchi, Eiji
    Miyazaki, Jun
    Yuge, Kazuyuki
    Hagiwara, Masayuki
    Ichioka, Daishi
    Inoue, Takamitsu
    Kageyama, Susumu
    Sugimoto, Mikio
    Mitsuzuka, Koji
    Matsui, Yoshiyuki
    Yamamoto, Shingo
    Kinoshita, Hidefumi
    Wakeda, Hironobu
    Hanai, Kazuya
    Nishiyama, Hiroyuki
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2016, 46 (02) : 163 - 169
  • [39] Comparing costs of renal preservation versus radical nephroureterectomy management among patients with non-metastatic upper tract urothelial carcinoma
    Williams, Stephen B.
    Shan, Yong
    Fero, Katherine E.
    Movva, Giri
    Baillargeon, Jacques
    Tyler, Douglas S.
    Chamie, Karim
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (07) : 345.e1 - 345.e7
  • [40] Survival Effect of Nephroureterectomy in Metastatic Upper Urinary Tract Urothelial Carcinoma
    Nazzani, Sebastiano
    Preisser, Felix
    Mazzone, Elio
    Marchioni, Michele
    Bandini, Marco
    Tian, Zhe
    Mistretta, Francesco A.
    Shariat, Shahrokh F.
    Soulieres, Denis
    Saad, Fred
    Montanari, Emanuele
    Luzzago, Stefano
    Briganti, Alberto
    Carmignani, Luca
    Karakiewicz, Pierre, I
    CLINICAL GENITOURINARY CANCER, 2019, 17 (03) : E602 - E611